Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

Final appraisal determination

Final appraisal determination document (PDF 463 KB)

Committee papers (PDF 1.07 MB)

Committee papers (PDF 883 KB)

Draft guidance: 2

Appraisal consultation document (PDF 513 KB)

Committee papers (PDF 1.57 MB)

Draft guidance

Committee papers (PDF 6.16 MB)

Appraisal consultation document (PDF 515 KB)

Equality impact assessment (Scoping) (PDF 73 KB)

Final scope (PDF 87 KB)

Final matrix (PDF 90 KB)

Comments table (PDF 132 KB)

Leukaemia (chronic lymphocytic) - ibrutinib: provisional matrix (post-referral) - July 2015 (PDF 91 KB)

Leukaemia (chronic lymphocytic) - ibrutinib: draft scope for consultation (post-referral) - July 2015 (PDF 93 KB)

Leukaemia (chronic lymphocytic) - ibrutinib: draft scope (pre-referral) - June 2014 (PDF 106 KB)

Leukaemia (chronic lymphocytic) - ibrutinib: provisional matrix (pre-referral) - June 2014 (PDF 102 KB)